Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 19;12(11):963. doi: 10.1038/s41419-021-04230-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021, corrected publication 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — A Sequence alignment of wild-type (WT) and mutated (Mut) putative miR-193b-3p-binding sites in the 3ʹ UTR of ERBB4. B Relative luciferase activities of plasmids carrying WT or mutant ERBB4 3ʹ UTR in 293 T cells co-transfected with miR-193b-3p mimics or miR-NC. Each bar represents mean ± SEM (n = 6). ^***P < 0.001, ns: no significant difference, compared with the indicated controls. C Representative blots showing protein levels of ERBB4 in HaCaT cells transfected with miR-193b-3p mimics (miR-193) or miR-193b-3p inhibitors (in-193) and their indicated CTLs (miR-NC and in-NC). Protein levels were detected by western blotting. GAPDH was used as a protein loading control. D The mRNA levels of ERBB4 in HaCaT cells transfected with miR-193b-3p mimics (miR-193) or miR-193b-3p inhibitors (in-193) were examined by qRT-PCR. Each bar represents mean ± SEM (n = 3). ns: no significant difference, compared with the indicated controls. E The mRNA levels of ERBB4 in NHKs transfected with miR-193b-3p mimics (miR-193) or miR-193b-3p inhibitors (in-193) were examined by qRT-PCR. Each bar represents mean ± SEM (n = 3). ns: no significant difference, compared with the indicated controls. F The mRNA levels of ERBB4 in skin tissues derived from healthy donors (CTL, n = 5) and psoriasis patients (Psoriasis, n = 6) were examined by qRT-PCR. GAPDH was used as the internal control. Each bar represents mean ± SEM. ns: no significant difference, compared with the indicated controls. G Left panel: ERBB4, STAT3, and NF-κB levels were analyzed in healthy (Normal) and psoriasis lesional skin samples (Psoriasis lesional) using immunohistochemistry. Scale bar = 50 µm. Right panel: quantification of ERBB4, STAT3, and NF-κB positivity in clinical samples (Normal control, n = 5; Psoriasis lesional, n = 6). Each bar represents mean ± SEM. ^***P < 0.001, compared with the indicated controls. H Left panel: Erbb4 levels were analyzed in mouse back skins of different groups using immunohistochemistry. Scale bar = 50 µm. Right panel: quantification of Erbb4 positivity in the skin tissues derived from different groups. Each bar represents mean ± SEM (n = 8 for each group). ^***P < 0.001, compared with the indicated controls. Vehicle means mice injected with agomiR-NC and treated with Vaseline, agomiR-NC + IMQ and agomiR-193 + IMQ means mice injected with agomiR-NC and agomiR-193, respectively, and then treated with IMQ for 5 consecutive days. I Left panel: correlation of miR-193b-3p expression and Erbb4 protein positivity in IMQ-induced psoriasis mouse model (n = 16). Right panel: correlation of miR-193b-3p expression and ERBB4 protein positivity in clinical samples (n = 11).